Hjem › Ikke-småcellet lungekreft › Illinois › Arlington Heights
Kliniske studier for Ikke-småcellet lungekreft i Arlington Heights, IL
12 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Arlington Heights (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- Advocate Good Shepherd Hospital, Barrington · 9 mi unna
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
RekruttererFase 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
RekruttererFase 3
- Illinois Cancer Specialists, Arlington Heights
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
RekruttererObservasjonsstudie
- Northwest Oncology & Hematology, Elk Grove Village · 6 mi unna
An External Control Arm Study in Non-Small Cell Lung Cancer
RekruttererObservasjonsstudie
- Northwest Oncology and Hematology, Rolling Meadows · 2 mi unna
- Northwest Oncology and Hematology, Elk Grove · 6 mi unna
- Northwest Oncology and Hematology, Hoffman Estates · 6 mi unna
- og 1 flere
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RekruttererFase 2/3
- Local Institution - 007-883-A, Arlington Heights
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
RekruttererFase 3
- Illinois Cancer Specialists, Arlington Heights
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RekruttererFase 3
- Northwest Oncology & Hematology, Barrington · 9 mi unna
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- Advocate Good Shepherd Hospital, Barrington · 9 mi unna
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- Advocate Good Shepherd Hospital, Barrington · 9 mi unna
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- Advocate Good Shepherd Hospital, Barrington · 9 mi unna
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
RekruttererObservasjonsstudie
- Advocate Good Shepherd Hospital, Barrington · 9 mi unna
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Arlington Heights
- Kolorektal kreft12 studier
- Lungekreft9 studier
- Brystkreft7 studier
- Hjertesvikt7 studier
- Metastatisk kreft6 studier
- Ulcerøs kolitt6 studier
- Tykktarmskreft6 studier
- Eggstokkreft5 studier
- Fedme5 studier
- Overvekt5 studier
- Prostatakreft3 studier
- Hudtilstander3 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.